SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has fueled fears of a broader correction, with traders invoking the Black Monday anniversary and questioning whether AI spending concerns could deepen the pressure. A futures rebound sparked short-squeeze hopes, but others see a potential bull trap ahead of major tech earnings.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under pressure amid staggered IPO lockup releases that make additional shares eligible for sale, with traders debating whether potential insider selling will add to the decline or is already priced in. Broader weakness in AI and semiconductor stocks and concerns about valuation and customer concentration weigh on sentiment, while some investors are buying the dip.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has turned the Black Monday crash chatter into a debate over whether bears are being squeezed or the bounce is a low-volume bull trap that could fade at the cash open. Some traders speculate that hopes for Russia-Ukraine progress and easing oil prices are helping sentiment, but the moves durability remains uncertain.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the focus, with traders watching for the 80th death event that triggers final analysis; the last disclosed count was 78, and the company has not confirmed that the threshold has been reached. The prolonged wait and company silence fuel opposing views: some see a possible survival benefit from GPS, while others worry about the delay and question speculation that ASH embargoes or the companys booth signal an upcoming readout; shares have faced sharp selling.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad selloff in AI infrastructure and neocloud stocks, as investors question debt-funded expansion, financing costs and whether providers can earn adequate returns; concerns around CoreWeave have added pressure across the sector. Traders are divided between expecting further downside as valuations reset and arguing Nebius has a stronger balance sheet and long-term contracts than some peers, making the drop excessive.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassians run to a 52-week high and breakout above a key trading level are drawing attention, with traders pointing to enterprise demand and customers migrating to its cloud products. Bulls see room for the software rally to continue, while others warn that the sharp advance may be overextended and vulnerable to a pullback.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas push into stablecoin payments is drawing attention alongside its move to fresh highs, with traders also citing momentum and China-market access as positives. The reaction is broadly bullish, though some warn the stock looks overextended or expensive.

Roundhill ETF Trust - Roundhill Memory ETF

DRAM is drawing attention amid a sharp selloff in memory stocks, with traders pointing to concerns about Chinese competitor CXMT, weakening memory prices, and whether AI data-center spending can sustain demand. Bulls argue memory supply remains tight and AI demand durable, while bears see growing oversupply and pressure on the AI trade.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

RIOT is drawing attention amid a sharp selloff across Bitcoin miners and AI/data-center-linked stocks, with traders pointing to Bitcoin weakness, broader market pressure, and doubts about the sectors capital-intensive AI pivot. Many are frustrated that RIOT has fallen even when Bitcoin holds up, while others are buying the dip and debating whether further downside lies ahead.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances ESMO results are the main focus, with traders highlighting durable frontline melanoma combination data and preliminary lifileucel activity in sarcoma. Reactions are mixed: bulls see support for expansion into new indications, while skeptics point to small cohorts and limited new information; many attribute the share decline to broader biotech weakness rather than a company-specific setback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity

Equity

The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August.


Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month. 


RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy

Wall Street raised Ultragenyx’s price target after the U.S. Food and Drug Administration approved Fayuvi to treat children with Sanfilippo syndrome Type A.


Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$14.54
Prev Close	$15.17
Open	$15.11
Dividend Yield	0.00%
50-Day Moving Average	$19.03
Beta	1.06
Avg. Volume	7.13M
PE Ratio	-2.49

52-Week High	$39.89
52-Week Low	$12.73
Market Capitalization	$1.43B
EPS (Annual)	-$5.83
Price to Book	-4.91
Revenue Per Employee	$490,882.57

Feed

News

Sentiment

Earnings

Fundamentals

Info

RARE Fundamentals